NCT05317000 — Barbara Burtness cancer immunotherapy trial
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Registry record
| Registry ID | NCT05317000 ↗ |
|---|---|
| Lead sponsor | Barbara Burtness |
| Collaborators | National Institute of Dental and Craniofacial Research (NIDCR) |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Squamous Cell Carcinoma of Head and Neck |
| Enrollment | 50 participants (target) |
| Start date | 2023-03-23 |
| Primary completion | 2028-06-30 (est.) |
| Last registry update | 10 Jun 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05317000), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
FAQ
What phase is NCT05317000?
NCT05317000 (5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC) is registered on ClinicalTrials.gov as Phase 2, sponsored by Barbara Burtness.
Is NCT05317000 recruiting?
As of the 2026-06-10 registry update, NCT05317000 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05317000?
The lead sponsor is Barbara Burtness. Collaborators: National Institute of Dental and Craniofacial Research (NIDCR).
What condition does NCT05317000 study?
The registered condition is Squamous Cell Carcinoma of Head and Neck. Primary completion is listed as 2028-06-30 (estimated).
Are results available for NCT05317000?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05317000.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.